Galectin Therapeutics CEO Peter G. Traber, M.D. Named Chair of the Conference for NASH Summit Europe 2017
September 25 2017 - 8:30AM
Galectin Therapeutics Inc. (NASDAQ:GALT), the leading
developer of therapeutics that target galectin proteins, announced
Peter G. Traber, M.D., the Company’s chief executive officer and
chief medical officer was named Chair of the Conference for NASH
Summit Europe 2017. The Summit, an industry nonalcoholic
steatohepatitis (NASH) drug development forum, will take place at
The Westin Grand Frankfurt in Frankfurt, Germany on October 10-12,
2017.
“Being named this year’s Chair of the Conference for NASH Summit
Europe recognizes all the hard work that Galectin has done to make
a breakthrough in this troubling disease,” says Dr. Traber. “With
no approved treatment and a patient population in the millions and
growing, NASH is a huge unmet medical need. NASH Summit Europe is
an important conference where the top clinicians and scientists
working on NASH can extensively discuss drug development challenges
to improve drug efficacy, robustly diagnose patient populations,
and identify novel targets that can translate to clinical
practice.”
Focused exclusively on NASH and replete with leading industry
experts, NASH Summit Europe is designed to provide the latest
insight and connections to solve the challenges many face from
drug discovery to late stage clinical development. The theme of
this year’s conference is “Accelerate the Development of Your
Nonalcoholic Steatohepatitis Drug Pipeline.”
“NASH has proven to be incredibly difficult to diagnose, in turn
creating a difficult drug development process,” adds Traber. “For
this reason, it is essential that both organizations developing a
drug as well as developing novel non-invasive diagnostic tests
collaborate to advance the treatment of NASH and accelerate the
timelines to when effective therapies are available to patients.”
As Chair of the Conference, Dr. Traber helped organize the
internationally renowned academic and industrial speakers at this
conference and will provide the opening and closing remarks on
October 11 and 12.
About Galectin TherapeuticsGalectin
Therapeutics is dedicated to developing novel therapies to
improve the lives of patients with chronic liver and skin diseases
and cancer. Galectin's lead drug (GR-MD-02) is a carbohydrate-based
drug that inhibits the galectin-3 protein that is directly involved
in multiple inflammatory, fibrotic, and malignant diseases. The
lead development program is in non-alcoholic steatohepatitis (NASH)
with cirrhosis, the most advanced form of NASH related fibrosis.
This is the most common liver disease and one of the largest drug
development opportunities available today. Additional development
programs are for treatment of severe atopic dermatitis,
moderate-to-severe plaque psoriasis, and in combination
immunotherapy for advanced melanoma and other malignancies.
Galectin seeks to leverage extensive scientific and development
expertise as well as established relationships with external
sources to achieve cost-effective and efficient development.
Additional information is available at
www.galectintherapeutics.com.
Contacts: Jack Callicutt, Chief Financial
Officer (678) 620-3186 ir@galectintherapeutics.com
Galectin Therapeutics (NASDAQ:GALT)
Historical Stock Chart
From Mar 2024 to Apr 2024
Galectin Therapeutics (NASDAQ:GALT)
Historical Stock Chart
From Apr 2023 to Apr 2024